Lupus & antiphospholipid syndrome
The SLE disease activity score (SLE-DAS) provides an accurate and feasible flare tool in the clinical setting: a validation study
Authors' conclusion
The SLE-DAS accurately identifies and categorizes flares as mild or moderate/severe.
Study context
- Population
- Patients with SLE in SLE-DAS low disease activity at baseline, two academic lupus clinics69 with flares
- Participants
- 442 patients
- Comparison
- SLE-DAS flare tool vs c-SELENA FI, r-SELENA FI and SLEDAI-2K against clinician gold-standard
- Outcome
- Sensitivity, specificity and Cohen's Kappa agreement of each flare tool vs gold-standard expert-defined flare
Methodological detailsvalidation study, two academic lupus clinics, expert-consensus-based definition as gold-standard
- Validation study
- Two academic lupus clinics
- Expert-consensus-based definition as gold-standard
Performance
As reported in the abstract
Flare identification vs gold-standard
| Test or model | Sensitivity | Specificity | Kappa |
|---|---|---|---|
| SLE-DAS | 97.1% | 97.3% | 0.902 (95% CI: 0.847, 0.957) |
| c-SELENA FI | 88.4% | 98.1% | 0.870 (95% CI: 0.805, 0.935) |
| r-SELENA FI | 88.4% | 96.8% | 0.832 (95% CI: 0.761, 0.903) |
| SLEDAI-2K | 56.5% | 99.2% | 0.663 (95% CI: 0.557, 0.769) |
Sensitivity
SLE-DAS97.1%
c-SELENA FI88.4%
r-SELENA FI88.4%
SLEDAI-2K56.5%
Specificity
SLE-DAS97.3%
c-SELENA FI98.1%
r-SELENA FI96.8%
SLEDAI-2K99.2%
Kappa
SLE-DAS0.902 (95% CI: 0.847, 0.957)
c-SELENA FI0.870 (95% CI: 0.805, 0.935)
r-SELENA FI0.832 (95% CI: 0.761, 0.903)
SLEDAI-2K0.663 (95% CI: 0.557, 0.769)
Further findings
- Expert-defined flares implying a treatment change identified by SLE-DAS
- 96.6%
Flare incidence · follow-up 22.9 (14.2) months
- Incidence of flares
- 8.19/100 patient-years
Original publication
The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study. Rheumatology (Oxford). Published 17 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →